Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Richard Rothman

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Brain

Procedures

Radioligand Assay

Concepts & Ideas

Structure-Activity Relationship

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
133
Rice, Kenner
82
Dersch, Christina
76
Baumann, Michael
65
Jacobson, Arthur
51
Partilla, John
36
Xu, Heng
32
carroll, Frank
23
Prisinzano, Thomas
17
Xu, H
15
Flippen-Anderson, Judith
13
Thomas, James
13
Wang, Xiaoying
13
Mascarella, Wayne
12
Matecka, Dorota
12
Ananthan, Subramaniam

Sign-in to see all Coauthors

Publications

TOP 3
Baumann Michael H; Zolkowska Dorota; Kim Insook; Scheidweiler Karl B; Rothman Richard B; Huestis Marilyn A
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.
Rothman Richard B; Baumann Michael H
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
Rothman Richard B; Baumann Michael H
Serotonergic drugs and valvular heart disease.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Richard Rothman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Baumann Michael H; Zolkowska Dorota; Kim Insook; Scheidweiler Karl B; Rothman Richard B; Huestis Marilyn A
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(11):2163-70.
2009: Rothman Richard B; Baumann Michael H
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
American journal of therapeutics 2009;16(4):354-64.
2009: Rothman Richard B; Baumann Michael H
Serotonergic drugs and valvular heart disease.
Expert opinion on drug safety 2009;8(3):317-29.
2009: Rothman Richard B; Dersch Christina M; Ananthan Subramaniam; Partilla John S
Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release.
The Journal of pharmacology and experimental therapeutics 2009;329(2):718-28.
2009: Zolkowska Dorota; Jain Raka; Rothman Richard B; Partilla John S; Roth Bryan L; Setola Vincent; Prisinzano Thomas E; Baumann Michael H
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
The Journal of pharmacology and experimental therapeutics 2009;329(2):738-46.
2009: Baumann Michael H; Rothman Richard B
Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).
International review of neurobiology 2009;88():257-96.
2008: Rothman Richard B; Zolkowska Dorota; Baumann Michael H
Serotonin (5-HT) transporter ligands affect plasma 5-HT in rats.
Annals of the New York Academy of Sciences 2008;1139():268-84.
2008: Xu Heng; Wang Xiaoying; Partilla John S; Bishop-Mathis Kristen; Benaderet Tova S; Dersch Christina M; Simpson Denise S; Prisinzano Thomas E; Rothman Richard B
Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
Brain research bulletin 2008;77(1):49-54.
2008: Zezula Josef; Singer Lisa; Przybyl Anna K; Hashimoto Akihiro; Dersch Christina M; Rothman Richard B; Deschamps Jeffrey; Lee Yong Sok; Jacobson Arthur E; Rice Kenner C
Synthesis and pharmacological effects of the enantiomers of the N-phenethyl analogues of the ortho and para e- and f-oxide-bridged phenylmorphans.
Organic & biomolecular chemistry 2008;6(16):2868-83.
2008: Rutherford John M; Wang Jiabei; Xu Heng; Dersch Christina M; Partilla John S; Rice Kenner C; Rothman Richard B
Evidence for a mu-delta opioid receptor complex in CHO cells co-expressing mu and delta opioid peptide receptors.
Peptides 2008;29(8):1424-31.
2008: Baumann Michael H; Clark Robert D; Rothman Richard B
Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.
Pharmacology, biochemistry, and behavior 2008;90(2):208-17.
2008: Pariser Joseph J; Partilla John S; Dersch Christina M; Ananthan Subramaniam; Rothman Richard B
Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release.
The Journal of pharmacology and experimental therapeutics 2008;326(1):286-95.
2008: Tidgewell Kevin; Groer Chad E; Harding Wayne W; Lozama Anthony; Schmidt Matthew; Marquam Alfred; Hiemstra Jessica; Partilla John S; Dersch Christina M; Rothman Richard B; Bohn Laura M; Prisinzano Thomas E
Herkinorin analogues with differential beta-arrestin-2 interactions.
Journal of medicinal chemistry 2008;51(8):2421-31.
2008: Baumann M H; Clark R D; Franken F H; Rutter J J; Rothman R B
Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.
Neuroscience 2008;152(3):773-84.
2008: Zolkowska Dorota; Baumann Michael H; Rothman Richard B
Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels.
The Journal of pharmacology and experimental therapeutics 2008;324(2):791-7.
2008: Rothman Richard B; Baumann Michael H; Prisinzano Thomas E; Newman Amy Hauck
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.
Biochemical pharmacology 2008;75(1):2-16.
2008: Rothman Richard B; Blough Bruce E; Baumann Michael H
Dopamine/serotonin releasers as medications for stimulant addictions.
Progress in brain research 2008;172():385-406.
2007: Holden Kenneth G; Tidgewell Kevin; Marquam Alfred; Rothman Richard B; Navarro Hernán; Prisinzano Thomas E
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
Bioorganic & medicinal chemistry letters 2007;17(22):6111-5.
2007: Wang X; Baumann M H; Dersch C M; Rothman R B
Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan.
Neuroscience 2007;148(1):212-20.
2007: Hiebel Anne-Cécile; Lee Yong Sok; Bilsky Edward; Giuvelis Denise; Deschamps Jeffrey R; Parrish Damon A; Aceto Mario D; May Everette L; Harris Louis S; Coop Andrew; Dersch Christina M; Partilla John S; Rothman Richard B; Cheng Kejun; Jacobson Arthur E; Rice Kenner C
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
Journal of medicinal chemistry 2007;50(16):3765-76.
2007: Simpson Denise S; Katavic Peter L; Lozama Anthony; Harding Wayne W; Parrish Damon; Deschamps Jeffrey R; Dersch Christina M; Partilla John S; Rothman Richard B; Navarro Hernan; Prisinzano Thomas E
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
Journal of medicinal chemistry 2007;50(15):3596-603.
2007: Cheng Kejun; Kim In Jong; Lee Mei-Jing; Adah Steven A; Raymond Tyler J; Bilsky Edward J; Aceto Mario D; May Everette L; Harris Louis S; Coop Andrew; Dersch Christina M; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.
Organic & biomolecular chemistry 2007;5(8):1177-90.
2007: Xu Heng; Partilla John S; Wang Xiaoying; Rutherford John M; Tidgewell Kevin; Prisinzano Thomas E; Bohn Laura M; Rothman Richard B
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
Synapse (New York, N.Y.) 2007;61(3):166-75.
2007: Groer C E; Tidgewell K; Moyer R A; Harding W W; Rothman R B; Prisinzano T E; Bohn L M
An opioid agonist that does not induce micro-opioid receptor--arrestin interactions or receptor internalization.
Molecular pharmacology 2007;71(2):549-57.
2007: Negus S S; Mello N K; Blough B E; Baumann M H; Rothman R B
Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics 2007;320(2):627-36.
2007: Rothman Richard B; Murphy Daniel L; Xu Heng; Godin Jonathan A; Dersch Christina M; Partilla John S; Tidgewell Kevin; Schmidt Matthew; Prisinzano Thomas E
Salvinorin A: allosteric interactions at the mu-opioid receptor.
The Journal of pharmacology and experimental therapeutics 2007;320(2):801-10.
2007: Gilbert Kathleen M; Boos Terrence L; Dersch Christina M; Greiner Elisabeth; Jacobson Arthur E; Lewis David; Matecka Dorota; Prisinzano Thomas E; Zhang Ying; Rothman Richard B; Rice Kenner C; Venanzi Carol A
DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods.
Bioorganic & medicinal chemistry 2007;15(2):1146-59.
2007: Ghitza Udi E; Rothman Richard B; Gorelick David A; Henningfield Jack E; Baumann Michael H
Serotonergic responsiveness in human cocaine users.
Drug and alcohol dependence 2007;86(2-3):207-13.
2007: Baumann Michael H; Wang Xiaoying; Rothman Richard B
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.
Psychopharmacology 2007;189(4):407-24.
2007: Rothman Richard B; Blough Bruce E; Baumann Michael H
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.
The AAPS journal 2007;9(1):E1-10.
2006: Rothman Richard B; Blough Bruce E; Baumann Michael H
Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction.
Trends in pharmacological sciences 2006;27(12):612-8.
2006: Partilla John S; Dempsey Allison G; Nagpal Ameet S; Blough Bruce E; Baumann Michael H; Rothman Richard B
Interaction of amphetamines and related compounds at the vesicular monoamine transporter.
The Journal of pharmacology and experimental therapeutics 2006;319(1):237-46.
2006: Rothman Richard B; Baumann Michael H
Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs.
Annals of the New York Academy of Sciences 2006;1074():245-60.
2006: Zolkowska Dorota; Rothman Richard B; Baumann Michael H
Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease.
The Journal of pharmacology and experimental therapeutics 2006;318(2):604-10.
2006: Kulkarni Santosh S; Nightingale Barbara; Dersch Christina M; Rothman Richard B; Newman Amy Hauck
Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists.
Bioorganic & medicinal chemistry letters 2006;16(13):3371-5.
2006: Tidgewell Kevin; Harding Wayne W; Lozama Anthony; Cobb Howard; Shah Kushal; Kannan Pavitra; Dersch Christina M; Parrish Damon; Deschamps Jeffrey R; Rothman Richard B; Prisinzano Thomas E
Synthesis of salvinorin A analogues as opioid receptor probes.
Journal of natural products 2006;69(6):914-8.
2006: Harding Wayne W; Schmidt Matthew; Tidgewell Kevin; Kannan Pavitra; Holden Kenneth G; Dersch Christina M; Rothman Richard B; Prisinzano Thomas E
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring.
Bioorganic & medicinal chemistry letters 2006;16(12):3170-4.
2006: Boos Terrence L; Greiner Elisabeth; Calhoun W Jason; Prisinzano Thomas E; Nightingale Barbara; Dersch Christina M; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter.
Bioorganic & medicinal chemistry 2006;14(11):3967-73.
2006: Wang Xiaoying; Xu Heng; Rothman Richard B
Regulation of the rat brain endothelin system by endogenous beta-endorphin.
Peptides 2006;27(4):769-74.
2006: Greiner Elisabeth; Boos Terrence L; Prisinzano Thomas E; De Martino Maria G; Zeglis Brian; Dersch Christina M; Marcus Jamila; Partilla John S; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.
Journal of medicinal chemistry 2006;49(5):1766-72.
2006: Harding Wayne W; Schmidt Matthew; Tidgewell Kevin; Kannan Pavitra; Holden Kenneth G; Gilmour Brian; Navarro Hernan; Rothman Richard B; Prisinzano Thomas E
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
Journal of natural products 2006;69(1):107-12.
2006: Rothman Richard B; Baumann Michael H
Therapeutic potential of monoamine transporter substrates.
Current topics in medicinal chemistry 2006;6(17):1845-59.
2005: Rothman Richard B; Baumann Michael H
Targeted screening for biogenic amine transporters: potential applications for natural products.
Life sciences 2005;78(5):512-8.
2005: Xu Heng; Wang Xiaoying; Zimmerman Darin; Boja Emily S; Wang Jiabei; Bilsky Edward J; Rothman Richard B
Chronic morphine up-regulates G alpha12 and cytoskeletal proteins in Chinese hamster ovary cells expressing the cloned mu opioid receptor.
The Journal of pharmacology and experimental therapeutics 2005;315(1):248-55.
2005: Wang Xiaoying; Baumann Michael H; Xu Heng; Morales Marisela; Rothman Richard B
(+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane.
The Journal of pharmacology and experimental therapeutics 2005;314(3):1002-12.
2005: Nightingale Barbara; Dersch Christina M; Boos Terrence L; Greiner Elisabeth; Calhoun William J; Jacobson Arthur E; Rice Kenner C; Rothman Richard B
Studies of the biogenic amine transporters. XI. Identification of a 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) analog that allosterically modulates the serotonin transporter.
The Journal of pharmacology and experimental therapeutics 2005;314(2):906-15.
2005: Harding Wayne W; Tidgewell Kevin; Byrd Nathan; Cobb Howard; Dersch Christina M; Butelman Eduardo R; Rothman Richard B; Prisinzano Thomas E
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
Journal of medicinal chemistry 2005;48(15):4765-71.
2005: Harding Wayne W; Tidgewell Kevin; Schmidt Matthew; Shah Kushal; Dersch Christina M; Snyder John; Parrish Damon; Deschamps Jeffrey R; Rothman Richard B; Prisinzano Thomas E
Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum.
Organic letters 2005;7(14):3017-20.
2005: Rothman Richard B; Blough Bruce E; Woolverton William L; Anderson Karen G; Negus S Stevens; Mello Nancy K; Roth Bryan L; Baumann Michael H
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.
The Journal of pharmacology and experimental therapeutics 2005;313(3):1361-9.
2005: Wee S; Anderson K G; Baumann M H; Rothman R B; Blough B E; Woolverton W L
Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs.
The Journal of pharmacology and experimental therapeutics 2005;313(2):848-54.
2005: Baumann Michael H; Clark Robert D; Budzynski Allison G; Partilla John S; Blough Bruce E; Rothman Richard B
N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(3):550-60.
2004: Baumann Michael H; Clark Robert D; Budzynski Allison G; Partilla John S; Blough Bruce E; Rothman Richard B
Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain.
Annals of the New York Academy of Sciences 2004;1025():189-97.
2004: Rothman Richard B; Jayanthi Subramaniam; Cadet Jean L; Wang Xiaoying; Dersch Christina M; Baumann Michael H
Substituted amphetamines that produce long-term serotonin depletion in rat brain ("neurotoxicity") do not decrease serotonin transporter protein expression.
Annals of the New York Academy of Sciences 2004;1025():151-61.
2004: Wang Xiaoying; Baumann Michael H; Xu Heng; Rothman Richard B
3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
Synapse (New York, N.Y.) 2004;53(4):240-8.
2004: Nandi Ayon; Dersch Christina M; Kulshrestha Manish; Ananthan Subramaniam; Rothman Richard B
Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter.
Synapse (New York, N.Y.) 2004;53(3):176-83.
2004: Kim In Jong; Dersch Christina M; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
A critical structural determinant of opioid receptor interaction with phenolic 5-phenylmorphans.
Bioorganic & medicinal chemistry 2004;12(16):4543-50.
2004: Xu Heng; Wang Xiaoying; Wang Jun; Rothman Richard B
Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Synapse (New York, N.Y.) 2004;52(3):209-17.
2004: Yu Han; Kim In Jong; Folk John E; Tian Xinrong; Rothman Richard B; Baumann Michael H; Dersch Christina M; Flippen-Anderson Judith L; Parrish Damon; Jacobson Arthur E; Rice Kenner C
Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters.
Journal of medicinal chemistry 2004;47(10):2624-34.
2004: Ananthan Subramaniam; Khare Naveen K; Saini Surendra K; Seitz Lainne E; Bartlett Jeffrey L; Davis Peg; Dersch Christina M; Porreca Frank; Rothman Richard B; Bilsky Edward J
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Journal of medicinal chemistry 2004;47(6):1400-12.
2004: Thomas James B; Fix Scott E; Rothman Richard B; Mascarella S Wayne; Dersch Christina M; Cantrell Buddy E; Zimmerman Dennis M; Carroll F Ivy
Importance of phenolic address groups in opioid kappa receptor selective antagonists.
Journal of medicinal chemistry 2004;47(4):1070-3.
2004: Carroll F Ivy; Zhang Li; Mascarella S Wayne; Navarro Hernán A; Rothman Richard B; Cantrell Buddy E; Zimmerman Dennis M; Thomas James B
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity.
Journal of medicinal chemistry 2004;47(2):281-4.
2004: Wang X; Xu H; Rothman R B
Intracerebroventricular administration of anti-endothelin-1 IgG selectively upregulates endothelin-A and kappa opioid receptors.
Neuroscience 2004;129(3):751-6.
2004: Baumann M H; Milchanowski A B; Rothman R B
Evidence for alterations in alpha2-adrenergic receptor sensitivity in rats exposed to repeated cocaine administration.
Neuroscience 2004;125(3):683-90.
2003: Rothman Richard B; Jayanthi Subramaniam; Wang Xiaoying; Dersch Christina M; Cadet Jean L; Prisinzano Thomas; Rice Kenner C; Baumann Michael H
High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain.
Synapse (New York, N.Y.) 2003;50(3):233-9.
2003: Kim In Jong; Ullrich Thomas; Janetka James W; Furness M Scott; Jacobson Arthur E; Rothman Richard B; Dersch Christina M; Flippen-Anderson Judith L; George Clifford; Rice Kenner C
Diaryldimethylpiperazine ligands with mu- and delta-opioid receptor affinity: Synthesis of (+)-4-[(alphaR)-alpha-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide and (-)-4-[(alphaR)-alpha-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide.
Bioorganic & medicinal chemistry 2003;11(22):4761-8.
2003: Rothman Richard B; Baumann Michael H
Monoamine transporters and psychostimulant drugs.
European journal of pharmacology 2003;479(1-3):23-40.
2003: Rothman Richard B; Vu Nga; Partilla John S; Roth Bryan L; Hufeisen Sandra J; Compton-Toth Beth A; Birkes Jon; Young Richard; Glennon Richard A
In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates.
The Journal of pharmacology and experimental therapeutics 2003;307(1):138-45.
2003: Ananthan Subramaniam; Khare Naveen K; Saini Surendra K; Davis Peg; Dersch Christina M; Porreca Frank; Rothman Richard B
Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Bioorganic & medicinal chemistry 2003;11(18):4143-54.
2003: Thomas James B; Atkinson Robert N; Vinson N Ariane; Catanzaro Jennifer L; Perretta Carin L; Fix Scott E; Mascarella S Wayne; Rothman Richard B; Xu Heng; Dersch Christina M; Cantrell Buddy E; Zimmerman Dennis M; Carroll F Ivy
Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
Journal of medicinal chemistry 2003;46(14):3127-37.
2003: Setola Vincent; Hufeisen Sandra J; Grande-Allen K Jane; Vesely Ivan; Glennon Richard A; Blough Bruce; Rothman Richard B; Roth Bryan L
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
Molecular pharmacology 2003;63(6):1223-9.
2003: Rothman Richard B; Clark Robert D; Partilla John S; Baumann Michael H
(+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters.
The Journal of pharmacology and experimental therapeutics 2003;305(3):1191-9.
2003: Greiner Elisabeth; Prisinzano Thomas; Johnson II Edward M; Dersch Christina M; Marcus Jamila; Partilla John S; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.
Journal of medicinal chemistry 2003;46(8):1465-9.
2003: Lewis David; Zhang Ying; Prisinzano Thomas; Dersch Christina M; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Further exploration of 1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]piperazine (GBR 12909): role of N-aromatic, N-heteroaromatic, and 3-oxygenated N-phenylpropyl substituents on affinity for the dopamine and serotonin transporter.
Bioorganic & medicinal chemistry letters 2003;13(7):1385-9.
2003: Rothman Richard B; Vu Nga; Wang Xiaoying; Xu Heng
Endogenous CART peptide regulates mu opioid and serotonin 5-HT(2A) receptors.
Peptides 2003;24(3):413-7.
2003: Hsin Ling-Wei; Prisinzano Thomas; Wilkerson Chavon R; Dersch Christina M; Horel Robert; Jacobson Arthur E; Rothman Richard B; Rice Kenner C
Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents.
Bioorganic & medicinal chemistry letters 2003;13(3):553-6.
2003: Ananthan Subramaniam; Kezar Hollis S; Saini Surendra K; Khare Naveen K; Davis Peg; Dersch Christina M; Porreca Frank; Rothman Richard B
Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
Bioorganic & medicinal chemistry letters 2003;13(3):529-32.
2003: Xu Heng; Lu Yi-Feng; Rothman Richard B
Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
Synapse (New York, N.Y.) 2003;47(1):1-9.
2002: Rothman Richard B; Vu Nga; Xu Heng; Baumann Michael H; Lu Yi-Feng
Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors.
Peptides 2002;23(12):2177-80.
2002: Schütz Johannes; Dersch Christina M; Horel Robert; Spetea Mariana; Koch Martin; Meditz Ruth; Greiner Elisabeth; Rothman Richard B; Schmidhammer Helmut
Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans.
Journal of medicinal chemistry 2002;45(24):5378-83.
2002: Hashimoto Akihiro; Jacobson Arthur E; Rothman Richard B; Dersch Christina M; George Clifford; Flippen-Anderson Judith L; Rice Kenner C
Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan.
Bioorganic & medicinal chemistry 2002;10(10):3319-29.
2002: Prisinzano Thomas; Greiner Elisabeth; Johnson Edward M; Dersch Christina M; Marcus Jamila; Partilla John S; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.
Journal of medicinal chemistry 2002;45(19):4371-4.
2002: Roth Bryan L; Baner Karen; Westkaemper Richard; Siebert Daniel; Rice Kenner C; Steinberg SeAnna; Ernsberger Paul; Rothman Richard B
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11934-9.
2002: Thomas James B; Atkinson Robert N; Namdev Nivedita; Rothman Richard B; Gigstad Kenneth M; Fix Scott E; Mascarella S Wayne; Burgess Jason P; Vinson N Ariane; Xu Heng; Dersch Christina M; Cantrell Buddy E; Zimmerman Dennis M; Carroll F Ivy
Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans.
Journal of medicinal chemistry 2002;45(16):3524-30.
2002: Ananthan Subramaniam; Saini Surendra K; Khare Rashmi; Clayton Sarah D; Dersch Christina M; Rothman Richard B
Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines.
Bioorganic & medicinal chemistry letters 2002;12(16):2225-8.
2002: Rothman Richard B; Baumann Michael H
Therapeutic and adverse actions of serotonin transporter substrates.
Pharmacology & therapeutics 2002;95(1):73-88.
2002: Rothman Richard B; Katsnelson Marina; Vu Nga; Partilla John S; Dersch Christina M; Blough Bruce E; Baumann Michael H
Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain.
European journal of pharmacology 2002;447(1):51-7.
2002: Rothman Richard B; Blough Bruce E; Baumann Michael H
Appetite suppressants as agonist substitution therapies for stimulant dependence.
Annals of the New York Academy of Sciences 2002;965():109-26.
2002: Baumann Michael H; Phillips Jennifer M; Ayestas Mario A; Ali Syed F; Rice Kenner C; Rothman Richard B
Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence.
Annals of the New York Academy of Sciences 2002;965():92-108.
2002: Baumann Michael H; Ayestas Mario A; Sharpe Lawrence G; Lewis David B; Rice Kenner C; Rothman Richard B
Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate.
The Journal of pharmacology and experimental therapeutics 2002;301(3):1190-7.
2002: Rothman Richard B; Carroll F Ivy; Morales Marisela; Rowley Daniel L; Rice Kenner C; Dersch Christina M; Donovan David M
Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice.
Synapse (New York, N.Y.) 2002;44(2):94-105.
2002: Rothman Richard B; Baumann Michael H
Serotonin releasing agents. Neurochemical, therapeutic and adverse effects.
Pharmacology, biochemistry, and behavior 2002;71(4):825-36.
2002: Hsin Ling-Wei; Dersch Christina M; Baumann Michael H; Stafford David; Glowa John R; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine.
Journal of medicinal chemistry 2002;45(6):1321-9.
2002: Rothman Richard B; Dersch Christina M; Carroll F Ivy; Ananthan Subramaniam
Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding.
Synapse (New York, N.Y.) 2002;43(4):268-74.
2002: Yu Han; Prisinzano Thomas; Dersch Christina M; Marcus Jamila; Rothman Richard B; Jacobson Arthur E; Rice Kenner C
Synthesis and biological activity of 8beta-substituted hydrocodone indole and hydromorphone indole derivatives.
Bioorganic & medicinal chemistry letters 2002;12(2):165-8.
2001: Zhang Y; Joseph D B; Bowen W D; Flippen-Anderson J L; Dersch C M; Rothman R B; Jacobson A E; Rice K C
Synthesis and biological evaluation of tropane-like 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909) analogues.
Journal of medicinal chemistry 2001;44(23):3937-45.
2001: Ullrich T; Dersch C M; Rothman R B; Jacobson A E; Rice K C
Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor.
Bioorganic & medicinal chemistry letters 2001;11(21):2883-5.
2001: Thomas J B; Atkinson R N; Rothman R B; Fix S E; Mascarella S W; Vinson N A; Xu H; Dersch C M; Lu Y; Cantrell B E; Zimmerman D M; Carroll F I
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.
Journal of medicinal chemistry 2001;44(17):2687-90.
2001: Xu H; Lu Y F; Rice K C; Ananthan S; Rothman R B
SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Brain research bulletin 2001;55(4):507-11.
2001: Xu H; Lu Y F; Thomas J B; Carroll F I; Rice K C; Rothman R B
Opioid peptide receptor studies. 15. Relative efficacy of 4-[(N-allyl-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide and related compounds at the cloned human delta-opioid receptor.
Synapse (New York, N.Y.) 2001;40(4):269-74.
2001: Baumann M H; Rothman R B; Pablo J P; Mash D C
In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.
The Journal of pharmacology and experimental therapeutics 2001;297(2):531-9.
2001: Baumann M H; Ayestas M A; Dersch C M; Rothman R B
1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;24(5):492-501.
2001: McLamore S; Ullrich T; Rothman R B; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson A E; Rice K C
Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
Journal of medicinal chemistry 2001;44(9):1471-4.
2001: Thomas J B; Herault X M; Rothman R B; Atkinson R N; Burgess J P; Mascarella S W; Dersch C M; Xu H; Flippen-Anderson J L; George C F; Carroll F I
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
Journal of medicinal chemistry 2001;44(6):972-87.
2001: Pepper J P; Baumann M H; Ayestas M; Rothman R B
Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens.
Brain research. Molecular brain research 2001;87(2):184-9.
2001: Xu H; Hashimoto A; Rice K C; Jacobson A E; Thomas J B; Carroll F I; Lai J; Rothman R B
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assay.
Synapse (New York, N.Y.) 2001;39(1):64-9.
2001: Rothman R B; Baumann M H; Dersch C M; Romero D V; Rice K C; Carroll F I; Partilla J S
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
Synapse (New York, N.Y.) 2001;39(1):32-41.
2001: Baumann M H; Pablo J; Ali S F; Rothman R B; Mash D C
Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine.
The Alkaloids. Chemistry and biology 2001;56():79-113.
2000: Partilla J S; Dersch C M; Yu H; Rice K C; Rothman R B
Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (-)-HY038.
Brain research bulletin 2000;53(6):821-6.
2000: Yu H; Rothman R B; Dersch C M; Partilla J S; Rice K C
Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters.
Bioorganic & medicinal chemistry 2000;8(12):2689-92.
2000: Gu X H; Yu H; Jacobson A E; Rothman R B; Dersch C M; George C; Flippen-Anderson J L; Rice K C
Design, synthesis, and monoamine transporter binding site affinities of methoxy derivatives of indatraline.
Journal of medicinal chemistry 2000;43(25):4868-76.
2000: Zhang Y; Rothman R B; Dersch C M; de Costa B R; Jacobson A E; Rice K C
Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909).
Journal of medicinal chemistry 2000;43(25):4840-9.
2000: Rothman R B; Baumann M H; Savage J E; Rauser L; McBride A; Hufeisen S J; Roth B L
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
Circulation 2000;102(23):2836-41.
2000: Baumann M H; Pablo J P; Ali S F; Rothman R B; Mash D C
Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.
Annals of the New York Academy of Sciences 2000;914():354-68.
2000: Baumann M H; Ayestas M A; Dersch C M; Partilla J S; Rothman R B
Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity.
Annals of the New York Academy of Sciences 2000;914():172-86.
2000: Rothman R B; Partilla J S; Dersch C M; Carroll F I; Rice K C; Baumann M H
Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addiction.
Annals of the New York Academy of Sciences 2000;914():71-81.
2000: Furness M S; Zhang X; Coop A; Jacobson A E; Rothman R B; Dersch C M; Xu H; Porreca F; Rice K C
Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective delta-opioid receptor agonists from 4-[(alphaR)-alpha-(2S,5R)-4-substituted-2, 5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and their enantiomers.
Journal of medicinal chemistry 2000;43(16):3193-6.
2000: Thomas J B; Atkinson R N; Rothman R B; Burgess J P; Mascarella S W; Dersch C M; Xu H; Carroll F I
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
Bioorganic & medicinal chemistry letters 2000;10(11):1281-4.
2000: Baumann M H; Rothman R B; Ali S F
Comparative neurobiological effects of ibogaine and MK-801 in rats.
Drug and alcohol dependence 2000;59(2):143-51.
2000: Baumann M H; Ayestas M A; Dersch C M; Brockington A; Rice K C; Rothman R B
Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications.
Synapse (New York, N.Y.) 2000;36(2):102-13.
2000: Rothman R B; Gorelick D A; Heishman S J; Eichmiller P R; Hill B H; Norbeck J; Liberto J G
An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
Journal of substance abuse treatment 2000;18(3):277-81.
2000: Heyliger S O; Ni Q; Rothman R B
Resolution of two [(35)S]GTP-gamma-S binding sites and their response to chronic morphine treatment: a binding surface analysis.
Brain research bulletin 2000;51(4):357-62.
2000: Rothman R B; Partilla J S; Baumann M H; Dersch C M; Carroll F I; Rice K C
Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse.
Synapse (New York, N.Y.) 2000;35(3):222-7.
1999: Goodman C B; Heyliger S; Emilien B; Partilla J S; Yang H Y; Lee C H; Cadet J L; Rothman R B
Chronic exposure to antibodies directed against anti-opiate peptides alter delta-opioid receptor levels.
Peptides 1999;20(12):1419-24.
1999: Zhang X; Rice K C; Calderon S N; Kayakiri H; Smith L; Coop A; Jacobson A E; Rothman R B; Davis P; Dersch C M; Porreca F
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
Journal of medicinal chemistry 1999;42(26):5455-63.
1999: Coop A; Pinto J; Wang L; McCullough K; Rothman R B; Dersch C; Jacobson A E; Rice K C
Delta opioid binding selectivity of 3-ether analogs of naltrindole.
Bioorganic & medicinal chemistry letters 1999;9(24):3435-8.
1999: Thomas J B; Atkinson R N; Herault X M; Rothman R B; Mascarella S W; Dersch C M; Xu H; Horel R B; Carroll F I
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
Bioorganic & medicinal chemistry letters 1999;9(23):3347-50.
1999: Lewis D B; Matecka D; Zhang Y; Hsin L W; Dersch C M; Stafford D; Glowa J R; Rothman R B; Rice K C
Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents.
Journal of medicinal chemistry 1999;42(24):5029-42.
1999: Heyliger S O; Jackson C; Rice K C; Rothman R B
Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
Synapse (New York, N.Y.) 1999;34(4):256-65.
1999: Donovan D M; Miner L L; Perry M P; Revay R S; Sharpe L G; Przedborski S; Kostic V; Philpot R M; Kirstein C L; Rothman R B; Schindler C W; Uhl G R
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression.
Brain research. Molecular brain research 1999;73(1-2):37-49.
1999: Romero D V; Partilla J S; Zheng Q X; Heyliger S O; Ni Q; Rice K C; Lai J; Rothman R B
Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.
Synapse (New York, N.Y.) 1999;34(2):83-94.
1999: Thomas J B; Herault X M; Rothman R B; Burgess J P; Mascarella S W; Xu H; Horel R B; Dersch C M; Carroll F I
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
Bioorganic & medicinal chemistry letters 1999;9(20):3053-6.
1999: Ananthan S; Kezar H S; Carter R L; Saini S K; Rice K C; Wells J L; Davis P; Xu H; Dersch C M; Bilsky E J; Porreca F; Rothman R B
Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Journal of medicinal chemistry 1999;42(18):3527-38.
1999: Rothman R B; Baumann M H; Dersch C M; Appel J; Houghten R A
Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library.
Synapse (New York, N.Y.) 1999;33(3):239-46.
1999: Rothman R B; Ayestas M A; Dersch C M; Baumann M H
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.
Circulation 1999;100(8):869-75.
1999: Coop A; Rothman R B; Dersch C; Partilla J; Porreca F; Davis P; Jacobson A E; Rice K C
delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
Journal of medicinal chemistry 1999;42(9):1673-9.
1999: Xu H; Lu Y F; Partilla J S; Zheng Q X; Wang J B; Brine G A; Carroll F I; Rice K C; Chen K X; Chi Z Q; Rothman R B
Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands.
Synapse (New York, N.Y.) 1999;32(1):23-8.
1999: Wojnicki F H; Rothman R B; Rice K C; Glowa J R
Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey.
The Journal of pharmacology and experimental therapeutics 1999;288(2):550-60.
1998: Thomas J B; Fall M J; Cooper J B; Rothman R B; Mascarella S W; Xu H; Partilla J S; Dersch C M; McCullough K B; Cantrell B E; Zimmerman D M; Carroll F I
Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
Journal of medicinal chemistry 1998;41(26):5188-97.
1998: Thomas J B; Mascarella S W; Burgess J P; Xu H; McCullough K B; Rothman R B; Flippen-Anderson J L; George C F; Cantrell B E; Zimmerman D M; Carroll F I
N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines are opioid receptor pure antagonists.
Bioorganic & medicinal chemistry letters 1998;8(22):3149-52.
1998: Baumann M H; Ayestas M A; Rothman R B
Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1998;18(21):9069-77.
1998: Baumann M H; Rothman R B
Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans.
Biological psychiatry 1998;44(7):578-91.
1998: Thomas J B; Zheng X; Mascarella S W; Rothman R B; Dersch C M; Partilla J S; Flippen-Anderson J L; George C F; Cantrell B E; Zimmerman D M; Carroll F I
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
Journal of medicinal chemistry 1998;41(21):4143-9.
1998: Rea W P; Rothman R B; Shippenberg T S
Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: concordance with clinical studies.
Synapse (New York, N.Y.) 1998;30(1):107-11.
1998: Ananthan S; Johnson C A; Carter R L; Clayton S D; Rice K C; Xu H; Davis P; Porreca F; Rothman R B
Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Journal of medicinal chemistry 1998;41(15):2872-81.
1998: Baumann M H; Rothman R B; Ali S F
Neurochemical and neuroendocrine effects of ibogaine in rats: comparison to MK-801.
Annals of the New York Academy of Sciences 1998;844():252-64.
1998: Baumann M H; Ayestas M A; Rothman R B
In vivo correlates of central serotonin function after high-dose fenfluramine administration.
Annals of the New York Academy of Sciences 1998;844():138-52.
1998: Rothman R B; Elmer G I; Shippenberg T S; Rea W; Baumann M H
Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction.
Annals of the New York Academy of Sciences 1998;844():59-74.
1998: Thomas J B; Mascarella S W; Rothman R B; Partilla J S; Xu H; McCullough K B; Dersch C M; Cantrell B E; Zimmerman D M; Carroll F I
Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
Journal of medicinal chemistry 1998;41(11):1980-90.
1998: Kubota H; Rothman R B; Dersch C; McCullough K; Pinto J; Rice K C
Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives.
Bioorganic & medicinal chemistry letters 1998;8(7):799-804.
1998: Rothman R B; Silverthorn M L; Glowa J R; Matecka D; Rice K C; Carroll F I; Partilla J S; Uhl G R; Vandenbergh D J; Dersch C M
Studies of the biogenic amine transporters. VII. Characterization of a novel cocaine binding site identified with [125I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate.
Synapse (New York, N.Y.) 1998;28(4):322-38.
1998: Lu Y F; Xu H; Liu-Chen L Y; Chen C; Partilla J S; Brine G A; Carroll F I; Rice K C; Lai J; Porreca F; Sadee W; Rothman R B
Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor.
Synapse (New York, N.Y.) 1998;28(2):117-24.
1998: Goodman C B; Heyliger S; Emilien B; Partilla J S; Yang H Y; Lee C H; Cadet J L; Rothman R B
Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptides.
Peptides 1998;19(10):1703-9.
1998: Ohuoha D C; Schindler C W; Rothman R B
Serotonin-4 receptor antagonists reverse cocaine-induced cardiac arrhythmia.
Life sciences 1998;63(19):1673-8.
1998: Ni Q; Xu H; Partilla J S; Rice K C; Matecka D; Calderon S N; Porreca F; Lai J; Schmidhammer H; Krassnig R; Rothman R B
Opioid peptide receptor studies. 9. Identification of a novel non-mu- non-delta-like opioid peptide binding site in rat brain.
Peptides 1998;19(6):1079-90.
1998: Heyliger S O; Payza K; Rothman R B
The effect of FMRFamide analogs on [35S]GTP-gamma-S stimulation in squid optic lobes.
Peptides 1998;19(4):739-47.
1998: Xu H; Lu Y F; Partilla J S; Pinto J; Calderon S N; Matecka D; Rice K C; Lai J; Porreca F; Ananthan S; Rothman R B
Opioid peptide receptor studies. 8. One of the mouse brain deltaNCX binding sites is similar to the cloned mouse opioid delta receptor: further evidence for heterogeneity of delta opioid receptors.
Peptides 1998;19(2):343-50.
1997: Katsura Y; Zhang X; Homma K; Rice K C; Calderon S N; Rothman R B; Yamamura H I; Davis P; Flippen-Anderson J L; Xu H; Becketts K; Foltz E J; Porreca F
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
Journal of medicinal chemistry 1997;40(18):2936-47.
1997: Shoaib M; Baumann M H; Rothman R B; Goldberg S R; Schindler C W
Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats.
Psychopharmacology 1997;131(3):296-306.
1997: Ohuoha D C; Maxwell J A; Thomson L E; Cadet J L; Rothman R B
Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study.
Journal of substance abuse treatment 1997;14(3):249-58.
1997: Glowa J R; Rice K C; Matecka D; Rothman R B
Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys.
Neuroreport 1997;8(6):1347-51.
1997: Matecka D; Lewis D; Rothman R B; Dersch C M; Wojnicki F H; Glowa J R; DeVries A C; Pert A; Rice K C
Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors.
Journal of medicinal chemistry 1997;40(5):705-16.
1997: Calderon S N; Rice K C; Rothman R B; Porreca F; Flippen-Anderson J L; Kayakiri H; Xu H; Becketts K; Smith L E; Bilsky E J; Davis P; Horvath R
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands.
Journal of medicinal chemistry 1997;40(5):695-704.
1996: Rothman R B; Ayestas M; Baumann M H
Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine.
Neuroreport 1996;8(1):7-9.
1996: Pickworth W B; Baumann M H; Fant R V; Rothman R B; Henningfield J E
Endocrine responses during acute nicotine withdrawal.
Pharmacology, biochemistry, and behavior 1996;55(3):433-7.
1996: Matecka D; Rothman R B; Radesca L; de Costa B R; Dersch C M; Partilla J S; Pert A; Glowa J R; Wojnicki F H; Rice K C
Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909).
Journal of medicinal chemistry 1996;39(24):4704-16.
1996: Glowa J R; Fantegrossi W E; Lewis D B; Matecka D; Rice K C; Rothman R B
Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909.
Journal of medicinal chemistry 1996;39(24):4689-91.
1996: Knapp R J; Santoro G; De Leon I A; Lee K B; Edsall S A; Waite S; Malatynska E; Varga E; Calderon S N; Rice K C; Rothman R B; Porreca F; Roeske W R; Yamamura H I
Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.
The Journal of pharmacology and experimental therapeutics 1996;277(3):1284-91.
1996: Baumann M H; Schuster C R; Rothman R B
Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain.
Drug and alcohol dependence 1996;41(1):71-4.
1996: Bertha C M; Ellis M; Flippen-Anderson J L; Porreca F; Rothman R B; Davis P; Xu H; Becketts K; Rice K C
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
Journal of medicinal chemistry 1996;39(10):2081-6.
1996: Elmer G I; Brockington A; Gorelick D A; Carrol F I; Rice K C; Matecka D; Goldberg S R; Rothman R B
Cocaine cross-sensitization to dopamine uptake inhibitors: unique effects of GBR12909.
Pharmacology, biochemistry, and behavior 1996;53(4):911-8.
1996: Bilsky E J; Bernstein R N; Hruby V J; Rothman R B; Lai J; Porreca F
Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.
The Journal of pharmacology and experimental therapeutics 1996;277(1):491-501.
1996: Elmer G I; Gorelick D A; Goldberg S R; Rothman R B
Acute sensitivity vs. context-specific sensitization to cocaine as a function of genotype.
Pharmacology, biochemistry, and behavior 1996;53(3):623-8.
1996: Baumann M H; Rothman R B
Chronic cocaine exposure potentiates prolactin and head shake responses to 5-HT2 receptor stimulation in rats.
Neuropharmacology 1996;35(3):295-301.
1996: Goodman C B; Emilien B; Becketts K; Cadet J L; Rothman R B
Downregulation of mu-opioid binding sites following chronic administration of neuropeptide FF (NPFF) and morphine.
Peptides 1996;17(3):389-97.
1995: Baumann M H; Gendron T M; Becketts K M; Henningfield J E; Gorelick D A; Rothman R B
Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers.
Biological psychiatry 1995;38(11):751-5.
1995: Bertha C M; Vilner B J; Mattson M V; Bowen W D; Becketts K; Xu H; Rothman R B; Flippen-Anderson J L; Rice K C
(E)-8-benzylidene derivatives of 2-methyl-5-(3-hydroxyphenyl)morphans: highly selective ligands for the sigma 2 receptor subtype.
Journal of medicinal chemistry 1995;38(24):4776-85.
1995: Cadet J L; Ladenheim B; Hirata H; Rothman R B; Ali S; Carlson E; Epstein C; Moran T H
Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice.
Synapse (New York, N.Y.) 1995;21(2):169-76.
1995: Cha X Y; Xu H; Ni Q; Partilla J S; Rice K C; Matecka D; Calderon S N; Porreca F; Lai J; Rothman R B
Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes.
Regulatory peptides 1995;59(2):247-53.
1995: Rothman R B; Xu H; Wang J B; Partilla J S; Kayakiri H; Rice K C; Uhl G R
Ligand selectivity of cloned human and rat opioid mu receptors.
Synapse (New York, N.Y.) 1995;21(1):60-4.
1995: Cadet J L; Ali S F; Rothman R B; Epstein C J
Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice.
Molecular neurobiology 1995;11(1-3):155-63.
1995: Rothman R B; Glowa J R
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.
Molecular neurobiology 1995;11(1-3):1-19.
1995: Baumann M H; Becketts K M; Rothman R B
Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats.
European journal of pharmacology 1995;282(1-3):87-93.
1995: Rothman R B; Silverthorn M L; Baumann M H; Goodman C B; Cadet J L; Matecka D; Rice K C; Carroll F I; Wang J B; Uhl G R
Studies of the biogenic amine transporters. VI. Characterization of a novel cocaine binding site, identified with [125I]RTI-55, in membranes prepared from whole rat brain minus caudate.
The Journal of pharmacology and experimental therapeutics 1995;274(1):385-95.
1995: Baumann M H; Rothman R B
Repeated cocaine administration reduces 5-HT1A-mediated prolactin secretion in rats.
Neuroscience letters 1995;193(1):9-12.
1995: Partilla J S; You J; Rothman R B
High-performance liquid chromatographic resolution of synthetic opiate and "anti-opiate" peptides from human plasma.
Journal of chromatography. B, Biomedical applications 1995;667(1):49-56.
1995: Brine G A; Stark P A; Liu Y; Carroll F I; Singh P; Xu H; Rothman R B
Enantiomers of diastereomeric cis-N-[1-(2-hydroxy-2-phenylethyl)- 3-methyl-4-piperidyl]-N-phenylpropanamides: synthesis, X-ray analysis, and biological activities.
Journal of medicinal chemistry 1995;38(9):1547-57.
1995: Bertha C M; Flippen-Anderson J L; Rothman R B; Porreca F; Davis P; Xu H; Becketts K; Cha X Y; Rice K C
Probes for narcotic receptor-mediated phenomena. 20. Alteration of opioid receptor subtype selectivity of the 5-(3-hydroxyphenyl)morphans by application of the message-address concept: preparation of delta-opioid receptor ligands.
Journal of medicinal chemistry 1995;38(9):1523-37.
1995: Bilsky E J; Calderon S N; Wang T; Bernstein R N; Davis P; Hruby V J; McNutt R W; Rothman R B; Rice K C; Porreca F
SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist.
The Journal of pharmacology and experimental therapeutics 1995;273(1):359-66.
1995: Silverthorn M L; Dersch C M; Baumann M H; Cadet J L; Partilla J S; Rice K C; Carroll F I; Becketts K M; Brockington A; Rothman R B
Studies of the biogenic amine transporters. V. Demonstration of two binding sites for the cocaine analog [125I]RTI-55 associated with the 5-HT transporter in rat brain membranes.
The Journal of pharmacology and experimental therapeutics 1995;273(1):213-22.
1995: Hirata H; Ladenheim B; Rothman R B; Epstein C; Cadet J L
Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals.
Brain research 1995;677(2):345-7.
1995: Xu H; Goodman C B; Partilla J S; Ni Q; Kayakiri H; Rice K C; Rothman R B
6 beta-[125iodo]-3, 14-dihydroxy-17-methyl-4, 5 alpha-epoxymorphinan ([125I]IOXY-AGO): a potent and selective radioligand for opioid mu receptors.
Synapse (New York, N.Y.) 1995;19(2):105-11.
1995: Ni Q; Xu H; Partilla J S; de Costa B R; Rice K C; Kayakiri H; Rothman R B
Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the kappa 2 receptor in guinea pig brain.
Peptides 1995;16(6):1083-95.
1995: Cha X Y; Xu H; Rice K C; Porreca F; Lai J; Ananthan S; Rothman R B
Opioid peptide receptor studies. 1. Identification of a novel delta-opioid receptor binding site in rat brain membranes.
Peptides 1995;16(2):191-8.
1994: Baumann M H; Char G U; De Costa B R; Rice K C; Rothman R B
GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat.
The Journal of pharmacology and experimental therapeutics 1994;271(3):1216-22.
1994: Rothman R B; Gorelick D A; Baumann M H; Guo X Y; Herning R I; Pickworth W B; Gendron T M; Koeppl B; Thomson L E; Henningfield J E
Lack of evidence for context-dependent cocaine-induced sensitization in humans: preliminary studies.
Pharmacology, biochemistry, and behavior 1994;49(3):583-8.
1994: Lai J; Ma S W; Zhu R H; Rothman R B; Lentes K U; Porreca F
Pharmacological characterization of the cloned kappa opioid receptor as a kappa 1b subtype.
Neuroreport 1994;5(16):2161-4.
1994: Rothman R B; Pert A
Effects of electroconvulsive shock on the retention of cocaine-induced conditioning.
Pharmacology, biochemistry, and behavior 1994;49(2):399-404.
1994: Bertha C M; Mattson M V; Flippen-Anderson J L; Rothman R B; Xu H; Cha X Y; Becketts K; Rice K C
A marked change of receptor affinity of the 2-methyl-5-(3-hydroxyphenyl)morphans upon attachment of an (E)-8-benzylidene moiety: synthesis and evaluation of a new class of sigma receptor ligands.
Journal of medicinal chemistry 1994;37(19):3163-70.
1994: Ni Q; Xu H; Partilla J S; de Costa B R; Rice K C; Borsodi A; Hosztafi S; Rothman R B
Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor binding.
Neurochemical research 1994;19(9):1159-63.
1994: Calderon S N; Rothman R B; Porreca F; Flippen-Anderson J L; McNutt R W; Xu H; Smith L E; Bilsky E J; Davis P; Rice K C
Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.
Journal of medicinal chemistry 1994;37(14):2125-8.
1994: Rothman R B; Cadet J L; Akunne H C; Silverthorn M L; Baumann M H; Carroll F I; Rice K C; de Costa B R; Partilla J S; Wang J B
Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55.
The Journal of pharmacology and experimental therapeutics 1994;270(1):296-309.
1994: Rothman R B
PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site.
Neurotoxicology and teratology 1994;16(4):343-53.
1994: Lai J; Bilsky E J; Rothman R B; Porreca F
Treatment with antisense oligodeoxynucleotide to the opioid delta receptor selectively inhibits delta 2-agonist antinociception.
Neuroreport 1994;5(9):1049-52.
1994: Akunne H C; Monn J A; Thurkauf A; Jacobson A E; Rice K C; Linders J T; Jiang Q; Porreca F; Rothman R B
An electrophilic affinity ligand based on (+)-MK801 distinguishes PCP site 1 from PCP site 2.
Neurochemical research 1994;19(4):385-9.
1994: Akunne H C; Dersch C M; Cadet J L; Baumann M H; Char G U; Partilla J S; de Costa B R; Rice K C; Carroll F I; Rothman R B
Studies of the biogenic amine transporters. III. Demonstration of two binding sites for [3H]GBR12935 and [3H]BTCP in rat caudate membranes.
The Journal of pharmacology and experimental therapeutics 1994;268(3):1462-75.
1994: Dersch C M; Akunne H C; Partilla J S; Char G U; de Costa B R; Rice K C; Carroll F I; Rothman R B
Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains.
Neurochemical research 1994;19(2):201-8.
1994: Rothman R B
A review of the effects of dopaminergic agents in humans: implications for medication development.
NIDA research monograph 1994;145():67-87.
1993: Ni Q; Xu H; Partilla J S; Stark P A; Carroll F I; Brine G A; Rothman R B
Stereochemical requirements for pseudoirreversible inhibition of opioid mu receptor binding by the 3-methylfentanyl congeners, RTI-46144 and its enantiomers: evidence for different binding domains.
Synapse (New York, N.Y.) 1993;15(4):296-306.
1993: Ni Q; Xu H; Partilla J S; de Costa B R; Rice K C; Rothman R B
Selective labeling of kappa 2 opioid receptors in rat brain by [125I]IOXY: interaction of opioid peptides and other drugs with multiple kappa 2a binding sites.
Peptides 1993;14(6):1279-93.
1993: Rothman R B; Brady L S; Xu H; Long J B
Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain.
Peptides 1993;14(6):1271-7.
1993: Baumann M H; Brockington A M; Rothman R B
Withdrawal from chronic cocaine enhances behavioral sensitivity to the 5-HT2/1C agonist DOI.
Biological psychiatry 1993;34(8):576-7.
1993: Xu H; Partilla J S; de Costa B R; Rice K C; Rothman R B
Differential binding of opioid peptides and other drugs to two subtypes of opioid delta ncx binding sites in mouse brain: further evidence for delta receptor heterogeneity.
Peptides 1993;14(5):893-907.
1993: Baumann M H; Raley T J; Partilla J S; Rothman R B
Biosynthesis of dopamine and serotonin in the rat brain after repeated cocaine injections: a microdissection mapping study.
Synapse (New York, N.Y.) 1993;14(1):40-50.
1993: Rothman R B; Lewis B; Dersch C; Xu H; Radesca L; de Costa B R; Rice K C; Kilburn R B; Akunne H C; Pert A
Identification of a GBR12935 homolog, LR1111, which is over 4,000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters.
Synapse (New York, N.Y.) 1993;14(1):34-9.
1993: Baumann M H; Rothman R B
Effects of acute and chronic cocaine on the activity of tuberoinfundibular dopamine neurons in the rat.
Brain research 1993;608(1):175-9.
1993: Rothman R B; Xu H; Char G U; Kim A; De Costa B R; Rice K C; Zimmerman D M
Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the kappa 2B (enkephalin-sensitive) binding site.
Peptides 1993;14(1):17-20.
1993: Rothman R B; Becketts K M; Radesca L R; de Costa B R; Rice K C; Carroll F I; Dersch C M
Studies of the biogenic amine transporters. II. A brief study on the use of [3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists.
Life sciences 1993;53(17):PL267-72.
1992: Rothman R B; Grieg N; Kim A; De Costa B R; Rice K C; Carroll F I; Pert A
Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter.
Pharmacology, biochemistry, and behavior 1992;43(4):1135-42.
1992: Akunne H C; de Costa B R; Jacobson A E; Rice K C; Rothman R B
[3H] cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine.
Neurochemical research 1992;17(12):1275-83.
1992: Xu H; Partilla J S; de Costa B R; Rice K C; Rothman R B
Interaction of opioid peptides and other drugs with multiple delta ncx binding sites in rat brain: further evidence for heterogeneity.
Peptides 1992;13(6):1207-13.
1992: Rothman R B; Mahboubi A; Bykov V; Kim C H; de Costa B R; Jacobson A E; Rice K C
Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that mu ligands are noncompetitive inhibitors of the delta cx opioid peptide binding site.
Peptides 1992;13(6):1137-43.
1992: Rothman R B
A review of the role of anti-opioid peptides in morphine tolerance and dependence.
Synapse (New York, N.Y.) 1992;12(2):129-38.
1992: Rothman R B; Bykov V; Xue B G; Xu H; De Costa B R; Jacobson A E; Rice K C; Kleinman J E; Brady L S
Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences.
Peptides 1992;13(5):977-87.
1992: Swain M G; Rothman R B; Xu H; Vergalla J; Bergasa N V; Jones E A
Endogenous opioids accumulate in plasma in a rat model of acute cholestasis.
Gastroenterology 1992;103(2):630-5.
1992: Rothman R B; Bykov V; Jacobson A E; Rice K C; Long J E; Bowen W D
A study of the effect of the irreversible delta receptor antagonist [D-Ala2,Leu5,Cys6]-enkephalin on delta cx and delta ncx opioid binding sites in vitro and in vivo.
Peptides 1992;13(4):691-4.
1992: de Costa B R; Iadarola M J; Rothman R B; Berman K F; George C; Newman A H; Mahboubi A; Jacobson A E; Rice K C
Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinan.
Journal of medicinal chemistry 1992;35(15):2826-35.
1992: Bergasa N V; Rothman R B; Vergalla J; Xu H; Swain M G; Jones E A
Central mu-opioid receptors are down-regulated in a rat model of cholestasis.
Journal of hepatology 1992;15(1-2):220-4.
1992: Akunne H C; Johannessen J N; de Costa B R; Rice K C; Rothman R B
MPTP lesions of the nigrostriatal dopaminergic projection decrease [3H]1-[1-(2-thienyl)cyclohexyl]piperidine binding to PCP site 2: further evidence that PCP site 2 is associated with the biogenic amine reuptake complex.
Neurochemical research 1992;17(3):261-4.
1992: de Costa B; Rothman R B; Bowen W D; Radesca L; Band L; Reid A; Paolo L D; Walker J M; Jacobson A E; Rice K C
Novel kappa opioid receptor and sigma ligands.
NIDA research monograph 1992;119():76-80.
1991: Rothman R B; Mele A; Reid A A; Akunne H C; Greig N; Thurkauf A; de Costa B R; Rice K C; Pert A
GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine.
Pharmacology, biochemistry, and behavior 1991;40(2):387-97.
1991: Akunne H C; Reid A A; Thurkauf A; Jacobson A E; de Costa B R; Rice K C; Heyes M P; Rothman R B
[3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex.
Synapse (New York, N.Y.) 1991;8(4):289-300.
1991: Rothman R B; Bykov V; Mahboubi A; Long J B; Jiang Q; Porreca F; de Costa B R; Jacobson A E; Rice K C; Holaday J W
Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
Synapse (New York, N.Y.) 1991;8(2):86-99.
1991: Xu H; Kim C H; Zhu Y C; Weber R J; Jacobson A E; Rice K C; Rothman R B
(+)-cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: evidence for pseudoallosteric modulation.
Neuropharmacology 1991;30(5):455-62.
1991: Rothman R B; Mahboubi A; Bykov V; Kim C H; Jacobson A E; Rice K C
Probing the opioid receptor complex with (+)-trans-superfit. I. Evidence that [D-Pen2,D-Pen5]enkephalin interacts with high affinity at the delta cx binding site.
Peptides 1991;12(2):359-64.
1991: Rothman R B; Reid A; Mahboubi A; Kim C H; De Costa B R; Jacobson A E; Rice K C
Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands.
Molecular pharmacology 1991;39(2):222-32.
1991: Rothman R B; Long J B; Bykov V; Xu H; Jacobson A E; Rice K C; Holaday J W
Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence.
Peptides 1991;12(1):151-60.
1991: Xu H; Ni Q; Jacobson A E; Rice K C; Rothman R B
Preliminary ligand binding data for subtypes of the delta opioid receptor in rat brain membranes.
Life sciences 1991;49(18):PL141-6.
1991: Rothman R B; Xu H; Seggel M; Jacobson A E; Rice K C; Brine G A; Carroll F I
RTI-4614-4: an analog of (+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for mu versus delta opioid binding sites.
Life sciences 1991;48(23):PL111-6.
1990: Qi J A; Bowen W D; Mosberg H I; Rothman R B; Porreca F
Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site.
The Journal of pharmacology and experimental therapeutics 1990;255(2):636-41.
1990: de Costa B R; Rice K C; Bowen W D; Thurkauf A; Rothman R B; Band L; Jacobson A E; Radesca L; Contreras P C; Gray N M
Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity sigma receptor ligands. Identification of a new class of highly potent and selective sigma receptor probes.
Journal of medicinal chemistry 1990;33(11):3100-10.
1990: Reid A A; Kim C H; Thurkauf A; Monn J A; de Costa B; Jacobson A E; Rice K C; Bowen W D; Rothman R B
Wash-resistant inhibition of phencyclidine- and haloperidol-sensitive sigma receptor sites in guinea pig brain by putative affinity ligands: determination of selectivity.
Neuropharmacology 1990;29(11):1047-53.
1990: Reid A A; Mattson M V; de Costa B R; Thurkauf A; Jacobson A E; Monn J A; Rice K C; Rothman R B
Specificity of phencyclidine-like drugs and benzomorphan opiates for two high affinity phencyclidine binding sites in guinea pig brain.
Neuropharmacology 1990;29(9):811-7.
1990: Rothman R B; Long J B; Bykov V; Jacobson A E; Rice K C; Holaday J W
Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors.
Neuropharmacology 1990;29(9):805-10.
1990: de Costa B R; Rothman R B; Bykov V; Band L; Pert A; Jacobson A E; Rice K C
Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacet amide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands.
Journal of medicinal chemistry 1990;33(4):1171-6.
1990: Rothman R B; Bykov V; de Costa B R; Jacobson A E; Rice K C; Brady L S
Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.
Peptides 1990;11(2):311-31.
1990: Band L; Xu H; Bykov V; Greig N; Kim C H; Newman A; Jacobson A E; Rice K C; Rothman R B
The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: evidence for a novel mechanism of action.
Life sciences 1990;47(24):2231-40.
1990: Reid A A; Monn J A; Jacobson A E; Rice K C; Rothman R B
Pseudoallosteric modulation by (+)-MK801 of NMDA-coupled phencyclidine binding sites.
Life sciences 1990;47(16):PL77-82.
1990: Rothman R B; Bykov V; de Costa B R; Jacobson A E; Rice K C; Brady L S
Evidence for four opioid kappa binding sites in guinea pig brain.
Progress in clinical and biological research 1990;328():9-12.
1990: Band L; de Costa B R; Bykov V; Pert A; Rice K C; Rothman R B
The affinity ligand "UPHIT" acylates kappa opioid binding sites in vivo.
Progress in clinical and biological research 1990;328():77-80.
1990: Rothman R B
High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development.
Life sciences 1990;46(20):PL17-21.
1990: Akunne H; deCosta B R; Rice K C; Jacobson A E; Rothman R B
Evidence for high and low affinity [3H]cocaine binding sites associated with the serotonin reuptake complex in guinea pig brain: allosteric modulation by paroxetine.
NIDA research monograph 1990;105():547-8.
1990: Rothman R B; Mele A; Reid A A; Akunne H; Grieg N; Thurkauf A; deCosta B R; Rice K C; Pert A
Preliminary evidence that the high affinity dopamine reuptake inhibitor, GBR12909, antagonizes the ability of cocaine to elevate extracellular levels of dopamine.
NIDA research monograph 1990;105():359-60.
1990: Reid A A; Bowen W D; Setterlund C; Rothman R B
The competitive NMDA receptor antagonist, CPP, allosterically modulates NMDA receptor associated PCP binding sites in the absence of steric hinderance.
NIDA research monograph 1990;105():339-40.
1990: Xu H; Kim C H; Zhu Y C; Weber R J; Rice K C; Rothman R B
Pseudoirreversible binding of opiates to opioid receptor subtypes in rat brain: a quantitative study.
NIDA research monograph 1990;105():410-1.
1990: Grayson N A; Rothman R B; Xu H; Rice K C
Pharmacological properties of (+)-buprenorphine and (+)-diprenorphine.
NIDA research monograph 1990;105():380-1.
1990: Rothman R B; Mahboubi A; Reid A A; Kim C H; deCosta B R; Jacobson A E; Rice K C
[3H]1,3-Di(2-tolyl)guanidine labels two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel blockers and sigma ligands.
NIDA research monograph 1990;105():335-6.
1990: Rothman R B; Yang H Y; Long J B
Upregulation of rat brain opioid receptors by the chronic administration of morphine: possible evidence for an anti-opiate model of tolerance and dependence.
NIDA research monograph 1990;105():264-70.
1989: Benkelfat C; Aulakh C S; Bykov V; Rice K C; De Costa B R; Rothman R B
Apparent down-regulation of rat brain mu- and kappa-opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine.
The Journal of pharmacy and pharmacology 1989;41(12):865-7.
1989: Rothman R B; Long J B; Holaday J W; Bykov V; de Costa B R; Kim C H; Jacobson A E; Rice K C
A study of the interaction of the alkylating agent, NIH10236, with opioid receptors in vitro and in vivo.
Neuropharmacology 1989;28(12):1349-56.
1989: Rothman R B; Reid A A; Monn J A; Jacobson A E; Rice K C
The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites.
Molecular pharmacology 1989;36(6):887-96.
1989: Rothman R B; Mele A; Reid A A; Akunne H; Greig N; Thurkauf A; Rice K C; Pert A
Tight binding dopamine reuptake inhibitors as cocaine antagonists. A strategy for drug development.
FEBS letters 1989;257(2):341-4.
1989: Heyman J S; Jiang Q; Rothman R B; Mosberg H I; Porreca F
Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists.
European journal of pharmacology 1989;169(1):43-52.
1989: Rothman R B; France C P; Bykov V; De Costa B R; Jacobson A E; Woods J H; Rice K C
Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.
European journal of pharmacology 1989;167(3):345-53.
1989: de Costa B R; Bowen W D; Hellewell S B; George C; Rothman R B; Reid A A; Walker J M; Jacobson A E; Rice K C
Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands.
Journal of medicinal chemistry 1989;32(8):1996-2002.
1989: de Costa B R; Band L; Rothman R B; Jacobson A E; Bykov V; Pert A; Rice K C
Synthesis of an affinity ligand ('UPHIT') for in vivo acylation of the kappa-opioid receptor.
FEBS letters 1989;249(2):178-82.
1989: Kim C H; Rothman R B; Jacobson A E; Mattson M V; Bykov V; Streaty R A; Klee W A; George C; Long J B; Rice K C
Probes for narcotic receptor mediated phenomena. 15. (3S,4S)-(+)-trans-3-methylfentanyl isothiocyanate, a potent site-directed acylating agent for the delta opioid receptors in vitro.
Journal of medicinal chemistry 1989;32(6):1392-8.
1989: Rothman R B; Bykov V; Long J B; Brady L S; Jacobson A E; Rice K C; Holaday J W
Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sites.
European journal of pharmacology 1989;160(1):71-82.
1989: Band L; Bykov V; Greig N; Kim C H; Hauck-Newman A; Jacobson A E; Rice K C; Rothman R B
In vivo binding of (+)-cis methylfentanyl at the opiate receptor complex and behavioral correlates: evidence for a novel mechanism of action.
NIDA research monograph 1989;95():554-5.
1989: Reid A A; Monn J A; Jacobson A E; Rice K C; Rothman R B
Characterization of NMDA-coupled and dopamine reuptake carrier coupled [3H]-TCP binding sites in guinea pig brain.
NIDA research monograph 1989;95():530-1.
1988: Rothman R B; Bykov V; Reid A; De Costa B R; Newman A H; Jacobson A E; Rice K C
A brief study of the selectivity of norbinaltorphimine, (-)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitro.
Neuropeptides 1988;12(3):181-7.
1988: Rothman R B; Bykov V; Newman A H; Jacobson A E; Rice K C
Interaction of enantiomeric pairs of opiates with phencyclidine binding sites in rat brain: identification of (+) pentazocine as a ligand potentially suitable for imaging sigma binding sites using positron emission tomography.
Neuropeptides 1988;12(1):1-5.
1988: Rothman R B; McLean S
An examination of the opiate receptor subtypes labeled by [3H]cycloFOXY: an opiate antagonist suitable for positron emission tomography.
Biological psychiatry 1988;23(5):435-58.
1988: Rothman R B; Bykov V; Ofri D; Rice K C
LY164929: a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site.
Neuropeptides 1988;11(1):13-6.
1988: Rothman R B; Bykov V; Rice K C; Jacobson A E; Kooper G N; Bowen W D
Tritiated-6-beta-fluoro-6-desoxy-oxymorphone ([3H]FOXY): a new ligand and photoaffinity probe for the mu opioid receptors.
Neuropeptides 1988;11(1):1-6.
1987: Rothman R B; Bykov V; Cadet J L; Kleinman J E
A postmortem study of the effect of chronic opiate abuse on psychotomimetic binding sites of human frontal cortex.
Neuropeptides 1987;10(3):261-4.

Sign-in to see more